Frost & Sullivan Independent Equity Research

RedHill announces top-line results from Phase III study of RHB-104 in Crohn’s Disease; cash balance improved with $25M (gross) raised at a discount; Top-line results for TALICIA® (RHB-105) – H. pylori infection expected by the end of 2018; target price reduced to NIS 2.23


Company: RedHill Biopharma Ltd.        

Sector: Pharmaceuticals

Report type: Q2-2018 Update Report

Published on: 4 September, 2018

RedHill research articles: